Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial

Wanpu Yan(Peking University), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Fan Yang(Peking University People's Hospital), Wei Shi(Jiangsu Hengrui Medicine (China)), Li Song(Harvard University), Lunxu Liu(Sichuan University), Wen‐Zhao Zhong(Guangdong Academy of Medical Sciences), Ke‐Neng Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Qin Zhang(Sichuan University), Yan‐Hui Liu(Hainan University), Wenqun Xing(Zhengzhou University), Qixun Chen(Zhejiang Cancer Hospital), Xiang Lin(University of Hong Kong), Di Ge(Nanjing University of Information Science and Technology)
Journal of Thoracic Oncology
October 1, 2022
10.1016/j.jtho.2022.09.222
Cited by 34

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k